|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-3-31
|
|
pubmed:abstractText |
Treatment of osteoporosis with bisphosphonates can lead to important reductions in fracture rates. The effectiveness of bisphosphonates is however limited by inadequate treatment persistence. The introduction of weekly administered forms has been associated with improved treatment persistence.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1778-7254
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
201-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17988921-Aged,
pubmed-meshheading:17988921-Aged, 80 and over,
pubmed-meshheading:17988921-Bone Density Conservation Agents,
pubmed-meshheading:17988921-Diphosphonates,
pubmed-meshheading:17988921-Dose-Response Relationship, Drug,
pubmed-meshheading:17988921-Drug Administration Schedule,
pubmed-meshheading:17988921-Female,
pubmed-meshheading:17988921-Fractures, Bone,
pubmed-meshheading:17988921-France,
pubmed-meshheading:17988921-Humans,
pubmed-meshheading:17988921-Models, Statistical,
pubmed-meshheading:17988921-Osteoporosis, Postmenopausal,
pubmed-meshheading:17988921-Public Health,
pubmed-meshheading:17988921-Sensitivity and Specificity,
pubmed-meshheading:17988921-Survival Analysis,
pubmed-meshheading:17988921-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France.
|
|
pubmed:affiliation |
Health Outcomes Studies, GlaxoSmithKline, Marly-le-Roi, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
